Trial Profile
A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Solriamfetol (Primary)
- Indications Sleep apnoea syndrome
- Focus Registrational; Therapeutic Use
- Acronyms TONES 3
- Sponsors Jazz Pharmaceuticals Inc
- 01 Nov 2022 Results of secondary analysis from two trials (TONES 2, TONES 3) assessing Efficacy and safety of Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depressionpublished in the Journal of Psychiatric Research
- 07 Sep 2022 According to an Axsome Therapeutics media release, post-hoc analysis results from NCT02348606 and NCT02348619 were published in the Journal of Psychiatric Research.
- 07 Sep 2022 Post-hoc analysis results from NCT02348606 and NCT02348619 published in an Axsome Therapeutics Media Release.